Flagellin Polypeptide-based Immune Modulation Platform

The present invention discloses a next-generation platform for modulating the immune response using flagellin polypeptides from Enterococcus gallinarum, incorporating cutting-edge technologies such as nanocarriers, gene editing tools, and bioinformatics to provide targeted, real-time, and personalized treatments.

The original patent disclosed pharmaceutical compositions comprising flagellin polypeptides from Enterococcus gallinarum for treating diseases. However, these compositions have limitations in terms of targeted delivery, real-time monitoring, and personalized treatment. The present inventive concept addresses these limitations by integrating advanced technologies to provide a more effective and efficient immune modulation platform.

The inventive concept comprises a system for modulating the immune response, including a first component with an isolated Enterococcus flagellin polypeptide, a second component with a nanocarrier for targeted delivery, and a third component with a bioinformatics tool for real-time monitoring. The system can be used in various applications, such as treating diseases, detecting the presence of Enterococcus gallinarum, and developing personalized medicine approaches. The inventive concept also encompasses methods for treating diseases using gene editing tools, vaccine compositions with synthetic adjuvants, and point-of-care diagnostic devices with microfluidic chips and nanosensors.

The present inventive concept is novel and non-obvious over the original patent due to the incorporation of advanced technologies, such as nanocarriers, gene editing tools, and bioinformatics, which provide targeted, real-time, and personalized treatments. The inventive concept's system and methods overcome the limitations of the original patent by providing more effective and efficient immune modulation.

Alternative embodiments of the inventive concept include using different types of nanocarriers, gene editing tools, and bioinformatics platforms. Variations of the inventive concept could also include using different flagellin polypeptides, modifying the pharmaceutical composition, or developing new point-of-care diagnostic devices.

The inventive concept has significant commercial potential in the fields of immunotherapy, vaccine development, and personalized medicine. The target market includes pharmaceutical companies, biotechnology firms, and healthcare providers seeking to develop more effective and efficient treatments for diseases.